PIPELINE WATCH

The pipeline keeps moving.

A static list becomes outdated quickly. RecompSignal follows emerging therapies by what is changing: trial readouts, regulatory milestones, body-composition signals and unanswered lean-mass questions.

Evidence reviewed: September 19, 2026 Educational research Source-labeled

What RecompSignal tracks

  • Clinical trial completions and major readouts
  • Regulatory milestones and indication changes
  • Direct fat-mass and lean-mass measurements
  • Mechanism-specific questions that have reached human testing

Current therapies to watch

Retatrutide Multi-agonist obesity program with advanced clinical evidence. CagriSema GLP-1 + amylin combination approach. MariTide Long-acting incretin candidate.
Important: investigational therapies are discussed as research programs, not as approved treatment recommendations.

Want the full evidence landscape?

Get the free 2026 Body-Recomposition Evidence Map with evidence maturity, body-composition signals and pipeline status in one reference.

Get the free Evidence Map

Related evidence

Evidence maturity Understand what M0–M5 means. Compare therapies Separate weight, composition and lean-mass evidence. Muscle preservation race Where new programs may differentiate.

New evidence and ongoing programs

Explore apitegromab, eloralintide, zenagamtide and the full 17-card directory. Published results, sponsor reports and registered studies are labeled separately.

Estimated trial completion dates can change and are not promised publication dates.

Pipeline explainerInvestigational

Retatrutide shows why mechanism and outcome evidence must remain separate.

Three receptor targets make the program scientifically distinctive. They do not, by themselves, establish superior fat selectivity, lean-mass preservation or function.

Open the Retatrutide Signal Card
Retatrutide triple agonist approach

The Triple-Agonist Approach

Mechanism is the beginning of the evidence story—not its conclusion.

Review the evidence →